A treatment for dry eye syndrome is to undergo a phase III randomized, placebo-controlled, multicentre study this year following a final licensing agreement with Celtic Therapeutics.
Resolvyx Pharmacuticals' RX-10045 is a resolvin that will be administered as a topical eye drop. In a large Phase II placebo-controlled study it was found that the eye drop produced dose-dependent, improvement on the primary endpoints for both signs and symptoms of dry eye, and was shown to be safe and well-tolerated.
Resolvins have demonstrated high potency and efficacy in the treatment of dry eye and retinal disease as well as asthma, rheumatoid arthritis, inflammatory bowel disease and atherosclerosis.
Stephen Evans-Freke and Peter B Corr, co-founders and Managing General Partners of Celtic Therapeutics Holdings, said: "We look forward to a close and successful alliance with Resolvyx to optimize the medical potential and financial returns from this exciting class of novel anti-inflammatory molecules in the ophthalmology field. If approved, RX-10045 should provide superior efficacy to current therapeutic options in dry eye. We are eager to explore the activity of resolvins in additional ophthalmic indications as well."